Imiglucerase in the management of Gaucher disease type 1: An evidence-based review of its place in therapy

Core Evidence

Volumn 11, Issue , 2016, Pages 37-47

  Serratrice, Christine ^a   Carballo, Sebastian ^a   Serratrice, Jacques ^a   Stirnemann, JéRome ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Disease; Imiglucerase; Lysosomal disease; Safety; Therapeutic goals; Treatment

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALGLUCERASE; CHITOTRIOSIDASE; DIPEPTIDYL CARBOXYPEPTIDASE; ELIGLUSTAT; FERRITIN; GLUCOSYLCERAMIDASE; IMIGLUCERASE; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN PARC; VELAGLUCERASE ALFA;

ARTHRALGIA; BONE DISEASE; CHILL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE REGISTRY; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG SAFETY; DYSPNEA; EVIDENCE BASED MEDICINE; FEVER; GAUCHER DISEASE; GAUCHER DISEASE TYPE 1; GROWTH RATE; HEMATOLOGICAL PARAMETERS; HUMAN; LUNG DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PROTEIN EXPRESSION; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SPLENECTOMY; SUBSTITUTION THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; URTICARIA;

EID: 84996486746     PISSN: 15551741     EISSN: 1555175X     Source Type: Journal    
DOI: 10.2147/CE.S93717     Document Type: Review

References (81)

1. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A 1990;87: 1913-1916.
2. de Fost M, Aerts JM, Groener JE, et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica 2007;92:215-221.
3. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-39.
4. Zimran A, Elstein D, Levy-Lahad E, et al. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995;345: 1479-1480.
5. Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 2008;73:430-440.
6. Maas M, van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging-initial experience. Radiology 2003;229:554-561.
7. Stirnemann J, Belmatoug N, Vincent C, Fain O, Fantin B, Mentre F. Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res Ther 2010;12:R156.
8. Smid BE, Ferraz MJ, Verhoek M, et al. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis 2016;11:28.
9. Murugesan V, Chuang WL, Liu J, et al. Glucosylsphingosine is a key biomarker of Gaucher Disease. Am J Hematol Epub July 21, 2016.
10. Czartoryska B, Tylki-Szymanska A, Gorska D. Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). Clin Biochem 1998;31:417-420.
11. Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol 2008;83:890-895.
12. Tukan I, Hadas-Halpern I, Altarescu G, Abrahamov A, Elstein D, Zimran A. Achievement of therapeutic goals with low-dose imiglucerase in Gaucher disease: a single-center experience. Adv Hematol.2013;2013:151506.
13. Doneda D, Netto CB, Moulin CC, Schwartz IV. Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. Nutr Metab (Lond) 2013;10:34.
14. Weinreb N, Barranger J, Packman S, et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 2007;71:576-588.
15. Deroma L, Sechi A, Dardis A, et al. Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 Italian Gaucher type I patients. JIMD Rep 2013;7: 117-122.
16. Beutler E Grabowski GA. Glucosylceramide lipidoses: Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D editors. The Metabolic Basis of Inherited Disease 7th ed. New York, NY: McGraw Hill; 1995:2641-2670.
17. Brady RO, Kanfer JN, Bradley RM, Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest 1966;45:1112-1115.
18. Qi X Grabowski GA. Molecular and cell biology of acid-beta glucosidase and prosaposin. Prog Nucleic Res Mol Biol 2001;66:203-239.
19. Tamargo RJ, Velayati A, Goldin E, Sidransky E. The role of saposin C in Gaucher disease. Mol Genet Metab 2012;106:257-263.
20. Stirnemann J, Belmatoug N. [Adult Gaucher disease]. Rev Med Interne 2001;22(Suppl 3):374s-383s. French.
21. Stirnemann J, Vigan M, Hamroun D, et al. The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis 2012;7:77.
22. Giraldo P, Alfonso P, Irun P, et al. Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula. Orphanet J Rare Dis 2012;7:17.
23. Raghavan SS, Topol J, Kolodny EH. Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease. Am J Hum Genet 1980;32:158-173.
24. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 2008;29:567-583.
25. Beighton P, Goldblatt J, Sacks S. Bone involvement in Gaucher disease. Prog Clin Biol Res 1982;95:107-129.
26. Brady RO, Barton NW, Grabowski GA. The role of neurogenetics in Gaucher disease. Arch Neurol 1993;50:1212-1224.
27. Mignot C, Doummar D, Maire I, De Villemeur TB. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 2006;28:39-48.
28. Sidransky E. Gaucher disease: insights from a rare Mendelian disorder. Discov Med 2012;14:273-281.
29. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE. 'Nonneuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis 2008;31:337-349.
30. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-1470.
31. Zimran A, Altarescu G, Philips M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010;115:4651-4656.
32. Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cellexpressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011;118: 5767-5773.
33. Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003;26:513-526.
34. Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116:893-899.
35. De Duve C. The lysosome. Sci Am 1963;208:64-72.
36. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N England Journal of Medicine. 1974;291(19):989-993.
37. Belchetz PE, Crawley JC, Braidman IP, Gregoriadis G. Treatment of Gaucher's disease with liposome-entrapped glucocerebroside: betaglucosidase. Lancet 1977;2:116-117.
38. Beutler E, Dale GL, Guinto DE, Kuhl W. Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation. Proc Natl Acad Sci U S A 1977;74:4620-4623.
39. Beutler E, Kay A, Saven A, et al. Enzyme replacement therapy for Gaucher disease. Blood 1991;78:1183-1189.
40. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160:2835-2843.
41. Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 2007;90:157-163.
42. Ref Imiglucerase®, Cerezyme Imiglucerase for injection. [prescribing information]. Cambridge, MA: Genzyme Corporation; 2011. Available from http://www.cerezyme.com, Accessed August 13, 2012.
43. Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 2009;147:561-570.
44. Rizk TM, Ariganjoye RO, Alsaeed GI. Gaucher disease. Unusual presentation and mini-review. Neurosciences (Riyadh) 2015;20:271-276.
45. Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM. [French results of enzyme replacement therapy in Gaucher's disease]. Bull Acad Natl Med 2002;186:851-861; discussion 61-63. French.
46. Kishnani PS, DiRocco M, Kaplan P, et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Mol Genet Metab 2009;96:164-170.
47. Ben Turkia H, Gonzalez DE, Barton NW, et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol 2012;88:179-184.
48. Weinreb NJ, Goldblatt J, Villalobos J, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 2012;36:543-553.
49. Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008;122:1182-1190.
50. Cox TM, Drelichman G, Cravo R, et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 2015;385:2355-2362.
51. Zimran A, Elstein D, Abrahamov A. Enzyme replacement therapy in type 1 and type 3 Gaucher's disease. Lancet 1995;345:451-452.
52. Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis 2011;46:66-72.
53. Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007;22:119-126.
54. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-1292.
55. Morgan MA, Hoffbrand AV, Laulicht M, Luck W, Knowles S. Serum ferritin concentration in Gaucher's disease. Br Med J (Clin Res Ed) 1983;286:1864.
56. Deegan PB, Moran MT, McFarlane I, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 2005;35:259-267.
57. Rolfs A, Giese AK, Grittner U, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One 2013;8:e79732.
58. Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med 2016;374:555-561.
59. Pavlova EV, Wang SZ, Archer J, et al. B cell lymphoma and myeloma in murine Gaucher's disease. J Pathol 2013;231:88-97.
60. Cabrera-Salazar MA, O'Rourke E, Henderson N, Wessel H, Barranger JA. Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta 2004;344:101-107.
61. Dekker N, van Dussen L, Hollak CE, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 2011;118:e118-e1127.
62. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41:4-14.
63. Kauli R, Zaizov R, Lazar L, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2000;2:158-163.
64. Dweck A, Abrahamov A, Hadas-Halpern I, Bdolach-Avram T, Zimran A, Elstein D. Type I Gaucher disease in children with and without enzyme therapy. Pediatr Hematol Oncol 2002;19:389-397.
65. Drelichman G, Ponce E, Basack N, et al. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr 2007;151:197-201.
66. Giraldo P, Solano V, Perez-Calvo JI, Giralt M, Rubio-Felix D. Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 2005;14:453-462.
67. Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK. Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 1999;8:263-268.
68. Damiano AM, Pastores GM, Ware JE, Jr. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 1998;7: 373-386.
69. Goitein O, Elstein D, Abrahamov A, et al. Lung involvement and enzyme replacement therapy in Gaucher's disease. QJM 2001;94:407-415.
70. Lo SM, Liu J, Chen F, et al. Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy. J Inherit Metab Dis. 2011;34:643-650.
71. Weinreb NJ. Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opin Pharmacother 2008;9:1987-2000.
72. Itzchaki M, Lebel E, Dweck A, et al. Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy. Acta Orthop Scand 2004;75:641-653.
73. Pastores GM, Shankar SP, Petakov M, et al. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase. Am J Hematol. 2016;91(7):661-665.
74. Elstein D, Mehta A, Hughes DA, et al. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease. Am J Hematol 2015;90:592-597.
75. Smith L, Rhead W, Charrow J, et al. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naive to enzyme replacement therapy or previously treated with imiglucerase. Mol Genet Metab. 2016;117:164-171.
76. Zimran A, Hollak CE, Abrahamov A, van Oers MH, Kelly M, Beutler E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 1993;82:1107-1109.
77. US Food and Drug Administration Cerezyme Label Information, 2005.: Available from http://www.accessdata.fda.gov/drugsatfda-docs/ label/2005/20367s066lbl.pdf. Accessed August 13, 2012.
78. Elstein D, Granovsky-Grisaru S, Rabinowitz R, Kanai R, Abrahamov A, Zimran A. Use of enzyme replacement therapy for Gaucher disease during pregnancy. Am J Obstet Gynecol 1997;177:1509-1512.
79. Zimran A, Morris E, Mengel E, et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 2009;43:264-288.
80. Granovsky-Grisaru S, Belmatoug N, vom Dahl S, Mengel E, Morris E, Zimran A. The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol 2011;156:3-8.
81. Sekijima Y, Ohashi T, Ohira S, Kosho T, Fukushima Y. Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk. Clin Ther. 2010; 32:2048-2052.